Validation of claims‐based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE‐J study

Aim Validity of Algorithms in Large Databases: Infectious Diseases, Rheumatoid Arthritis, and Tumor Evaluation in Japan (VALIDATE‐J) study examined algorithms for identifying rheumatoid arthritis (RA) in Japanese claims data. Methods VALIDATE‐J was a multicenter, cross‐sectional retrospective study....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:International journal of rheumatic diseases Ročník 27; číslo 1; s. e15001 - n/a
Hlavní autoři: Sugiyama, Naonobu, Kinjo, Mitsuyo, Jinno, Sadao, Luise, Cynthia, Morishima, Toshitaka, Higuchi, Takakazu, Katayama, Kayoko, Chen, Haoqian, Nonnenmacher, Edward, Hase, Ryota, Suzuki, Daisuke, Tanaka, Yoshiya, Setoguchi, Soko
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 01.01.2024
Témata:
Algorithms
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - epidemiology
claims‐based algorithm
Cross-Sectional Studies
Databases, Factual
Humans
Japan
Japan - epidemiology
positive predictive value
Psoriasis - drug therapy
Retrospective Studies
rheumatoid arthritis
United States
validation
United States
Japan
positive predictive value
claims-based algorithm
rheumatoid arthritis
Japan
validation
ISSN:1756-1841, 1756-185X, 1756-185X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Aim Validity of Algorithms in Large Databases: Infectious Diseases, Rheumatoid Arthritis, and Tumor Evaluation in Japan (VALIDATE‐J) study examined algorithms for identifying rheumatoid arthritis (RA) in Japanese claims data. Methods VALIDATE‐J was a multicenter, cross‐sectional retrospective study. Disease‐identifying algorithms were used to detect RA diagnosed between January 2012 and December 2016 using claims data from two Japanese hospitals. An RA diagnosis was confirmed using one of four gold standard definitions. Positive predictive values (PPVs) were calculated for prevalent (regardless of baseline RA‐free period) and incident (preceded by a 12‐month RA‐free period) cases. Results Of patients identified using claims‐based algorithms, a random sample of 389 prevalent and 134 incident cases of RA were included. Cases identified by an RA diagnosis, no diagnosis of psoriasis, and treatment with any disease‐modifying antirheumatic drugs (DMARDs) resulted in the highest PPVs versus other claims‐based treatment categories (29.0%–88.3% [prevalent] and 41.0%–78.2% [incident]); cases identified by an RA diagnosis, no diagnosis of psoriasis, and glucocorticoid‐only treatment had the lowest PPVs. Across claims‐based algorithms, PPVs were highest when a physician diagnosis or decision by adjudicators (confirmed and probable cases) was used as the gold standard and were lowest when American College of Rheumatology/European Alliance of Associations for Rheumatology 2010 criteria were applied. PPVs of claims‐based algorithms for RA in patients aged ≥66 years were slightly higher versus a USA Medicare population (maximum PPVs of 95.0% and 88.9%, respectively). Conclusion VALIDATE‐J demonstrated high PPVs for most claims‐based algorithms for diagnosis of prevalent and incident RA using Japanese claims data. These findings will help inform appropriate RA definitions for future claims database research in Japan.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1756-1841
1756-185X
1756-185X
DOI:10.1111/1756-185X.15001